Agmatine prevents LPS-induced spatial memory impairment and hippocampal apoptosis

Eur J Pharmacol. 2010 May 25;634(1-3):84-8. doi: 10.1016/j.ejphar.2010.02.029. Epub 2010 Feb 23.

Abstract

Neuroinflammation is associated with a number of neurodegenerative diseases. It is known that lipopolysaccharide (LPS) treatment induces neuroinflammation and memory deterioration. Agmatine, the metabolite of arginine by arginine decarboxylase, is suggested to be a neuroprotective agent. The aim of this study was to explore if agmatine can prevent LPS-induced spatial memory impairment and hippocampal apoptosis. Adult male Wistar rats (200-250 g) were trained in water maze for 4 days (3 days in hidden platform and the last day in visible platform task). Saline, LPS (250 microg/kg/ip) or (and) agmatine (5 or 10 mg/kg) were administered 4h before every training session. LPS treatment impaired water maze place learning while agmatine co-administration prevented it. Also western blot studies revealed that LPS induces hippocampal caspase-3 activation while agmatine treatment prevented it.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Agmatine / pharmacology
  • Agmatine / therapeutic use*
  • Animals
  • Apoptosis / drug effects*
  • Apoptosis / physiology
  • Hippocampus / drug effects*
  • Hippocampus / pathology
  • Lipopolysaccharides / toxicity*
  • Male
  • Maze Learning / drug effects
  • Maze Learning / physiology
  • Memory Disorders / chemically induced
  • Memory Disorders / prevention & control*
  • Rats
  • Rats, Wistar
  • Spatial Behavior / drug effects*
  • Spatial Behavior / physiology

Substances

  • Lipopolysaccharides
  • Agmatine